KATHERINE SPEARS: Open Payments
NPI 1346430261 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$563 in 28 payments from 8 companies in 2025. Trend: 2023 $279 · 2024 $207 · 2025 $563
Food & beverage: $563
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 10 | $174 |
| Janssen Pharmaceuticals, Inc | 5 | $113 |
| ABBVIE INC. | 5 | $107 |
| Neurocrine BioSciences, Inc. | 2 | $60 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Alkermes, Inc. | 1 | $17 |
Products named: REXULTI, VRAYLAR, INVEGA SUSTENNA, INGREZZA, CAPLYTA, UZEDY, INVEGA TRINZA, ABILIFY MAINTENA.
Industry payments across LA — which companies pay providers there.
